Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2005-08-09
2005-08-09
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S185100, C424S204100, C530S350000
Reexamination Certificate
active
06926897
ABSTRACT:
The invention relates to a medicament for preventing or treating human papilloma virus (HPV)-specific tumors containing at least one fusion protein and optional suitable additives and/or auxiliary agents. Said fusion protein is comprised of at least one L1-protein of one or more papilloma viruses, and is also comprised of at least one E-protein of one or more papilloma viruses, whereby the fusion protein does not contain any papilloma virus non-specific epitopes.
REFERENCES:
patent: 5618536 (1997-04-01), Lowy et al.
patent: 6066324 (2000-05-01), Gissmann et al.
patent: 6165471 (2000-12-01), Garcea et al.
patent: 343 783 (1989-04-01), None
patent: 390 252 (1990-03-01), None
patent: A-0565794 (1992-08-01), None
patent: WO 93/20844 (1933-10-01), None
patent: WO 90/10459 (1990-09-01), None
patent: WO 93/00436 (1993-01-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 93/21958 (1993-11-01), None
patent: WO 94/00152 (1994-01-01), None
patent: WO 94/05792 (1994-03-01), None
patent: WO 94/20137 (1994-09-01), None
patent: WO 96/00583 (1996-01-01), None
patent: WO 96/11272 (1996-04-01), None
patent: WO 96/11274 (1996-04-01), None
patent: WO 96/19496 (1996-06-01), None
patent: WO 98/04705 (1998-02-01), None
patent: WO 99/01557 (1999-01-01), None
patent: WO 94/23037 (2000-02-01), None
patent: WO 96/29091 (2000-08-01), None
Muller et al. 1997. Chimeric Papillomavirus-like Particles. Virology. vol. 234, pp. 93-111.
Hines et al. Feb. 1998. Prospects for human papillomavirus vacine development: emerging HPV vaccines. Current Opinion in Obstetrics and Gynecology. vol. 10, pp. 15-19.
Karasuyama et al., “Establishment Of Mouse Lines Which Constitutively Secrete Large Quantities Of Interleukin 2, 3, 4 Or 5, Using Modified cDNA Expression Vectors”,Immunol.,pp. 97-104, (1988).
G. Shaw et al., “Genetics”,A Conserved AU Sequence from the 3′ Untranslated Region of GM-CSF mRNA Mediates Selective mRNA Degradation,pp. 659-667 (1988).
M. Hagensee et al., “Journal of Virology”,Self-Assembly of Human Papillomavirus Type 1 Capsids by Expression of the L1 Protein Alone or by Coexpression of the L1 and L2 Capsid Proteins,pp. 315-322 (1993).
Xi et al., “Journal of General Virology”,Baculovirus expression of the human papillomavirus type 16 capsid proteins: detection of L1-L2 protein complexes,pp. 2981-2988 (1991).
R.C. Rose et al., “Journal of Virology”, vol. 67, No. 4,Expression of Human Papillomavirus Type 11 L1Protein in Insect Cells: In Vivo and In Vitro Assembly of Viruslike Particles,pp. 1936-1944, (Apr. 1993).
J. Zhou et al., “Virology”, vol. 185,Expression of Vaccinia Recombinant HPV 16 L1 and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Virion-like Particles,pp. 251-257, (1991).
M. S. Barbosa et al., “Journal of Virology”, vol. 65 No. 1,In Vitro Biological Activities of the E6 and E7 Genes Vary among Human Papillomaviruses of Different Oncogenic Potential,pp. 292-298, (Jan. 1991).
J.M. Arbeit et al., “Journal of Virology”, vol. 68,Progressive Squamous Epithelial neoplasia in K14-Human Papillomavirus Type 16 Transgenic Mice,pp. 4358-4368, (Jul. 1994).
P. Kaur et al., “J. Gen. Virology”, vol. 70,Immortalization of Primary Human Epithelial Cells by Cloned Cervical Carcinoma DNA Containing Human Papillomavirus Tyep 16 E6/E7 Open Reading Frames,pp. 1261-1266, (1989).
L. Gao et al., “Journal of General Virology”, vol. 75,Immune Response to Human Papillomavirus Type 16 E6 Gene in a Live Vaccinia Vector,pp. 157-164, (1994).
Tindle, et al., “Virology”,Chimeric Hepatisi B Core Antigen Particles Containing B- and Th-Epitopes of Human Papillomavirus type 16 E7 Protein Induce Spec. Antibody and T-Helper . . .pp. 547-557 (1994).
Kirnbauer et al., “Proc. Natl. Acad. Science”, Papillomavirus L1 major capsid protein self-assembles intovirus-like particles that are highly immunogenic,vol. 89, pp. 12180-12184 (1992).
Carter et al., “Virology”,Expression of Human Papillomavirus Proteins in Yeast Saccharomyces Cerevisiae,pp. 513-521 (1991).
Strike et al., Expression inEscherichia coliof Seven DNA Fragments Comprising the Complete L1 and L2 Open Reading Frames of Human Papillomavirus Type 6b and Localication of the ‘Common Antigen’ Region, Virology, pp. 543-555 (1989).
Schafer et al.,Immune Response to Human Papillomavirus 16 L1E7 Chimeric Virus-Like Particles: Induction of Cytotoxic T Cells and Specific Tumor Protection,“Int. J. Cancer” vol. 81, pp. 881-888 (1999).
Rose et al.,Expression of the full-length products of the human papillomavirus type 6b(HPB-6b)and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles.“Journal of General Virology”, vol. 71, pp. 2725-2729 (1990).
Muller et al.,Chimeric papillomavirus-like Particles,“Virology”, pp. 93-111 (1997).
J. Zhou et al., “Virology”, vol. 185,Identification of the Nuclear Localization Signal of Human Papillomavirus Type 16 L1 Protein,pp. 625-632, (1991).
R. Kirnbauer et al., “Journal of Virology”, vol. 67 No. 12,Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-Like Particles,pp. 6929-6936, (Dec. 1993).
J.A. Rawls et al., “Journal of Virology”, vol. 64 No. 12,Chemical Synthesis of Human Papillomavirus Type 16 E7 Oncoprotein: Autonomous Protein Domains for Induction of Cellular DNA Synthesis and for trans Activation,pp. 6121-6129, (Dec. 1990).
Paintsil, et al., “Virology”, vol. 223, pp. 238-244, (1996).
Greenstone et al., “Proc. Natl. Acad. Sci. USA”Chimeric Papillomavirus Virus-Like Particles Elicit Antitumor Immunity Against The E7 Oncoprotein in an HPV16 Tumor Model,vol. 95, pp. 1800-1805, (Feb. 1998).
Zhou et al., “Abstract From the 13thInternational Papillomavirus Conference”,Determination of L1 Sequences Required for 1Assembly of Bovine Papillomavirus (BPV) Capsids,Amsterdam, Netherlands, (Oct. 1994).
Zhou et al., “Glycosylation of Human Papillomavirus Type 16 L1 Protein”,Virology,194, pp. 210-218, (1993).
M. Li, et al.,Expression of the Human Papillomarvirus Type 11 L1 Capsid Protein in Escherichia coli: Characterization of Protein Domains Involved in DNA Binding and Capsid Assembly,Journal of Virology, vol. 71, No. 4, pgs. 2988-2995, (1997).
Altmann et al. “Towards HPV Vaccination,” inViruses and Cancer,Eds. Minson et al., Cambridge University Press, 71-80 (1994).
Balsley et al. “Progress in the Development of Human Papillomavirus Vaccines for HPV-11 and HPV-16/18 and Mapping of a Critical Neutralizing Epitope” Abstract from HPV 2000 Int. Papillomavirus Conf. 366.
Breitburd et al. J. Virol., 69: 3959-3963 (1995).
Campo “Vaccination Against Papillomavirus in Cattle” inCurrent Top Microbiol. Immunol: Human Pathogenic Papillomarivuses,Ed. Zur Hausen, Springer Verlag, Berlin, 186:255-266.
Christensen et al. “Human Papillomavirus Types 6 and 11 Have Antigenically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes,”Virology,205:329-335 (1994).
Christensen et al. “Assembled Baculovirus-Expressed Human Papillomavirus Type 11 L1 Capsid Protein Virus-Like Particles Are Recognized by Neutralizing Monoclonal Antibodies and Induce High Titres of Neutralizing Antibodies,”J. Gen. Virol.,75:2271-2276 (1994).
Crum et al. “Coexpression of the Human Papillomvirus Type 16 E4 and L1 Open Reading Frames in Early Cervical Neoplasia”Virology,Academic Press, 178: 238-246 (1990).
Crum et al. “Human Papillomavirus Type 16 and Early Cervical Neoplasia”N. Engl. J. Med.,Boston, MA, 310:880-883 (1984).
Dillner et al. “Antibodies Against Linear and Conformational Epitopes of Human Papillomavirus Type 16 that Independently Associate with Incident Cervical Cancer,”Int. J. Cancer,60: 377-382 (1995)
Burger Alexander
Hallek Michael
Foley Shanon
Housel James
MediGene Aktiengesellschaft
LandOfFree
Medicament for the avoidance or treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicament for the avoidance or treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament for the avoidance or treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468061